Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Fiche publication
Date publication
juillet 2009
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Pr BOUCHE Olivier, Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L
Lien Pubmed
Résumé
A previous study reported a significant survival benefit for octreotide compared with no treatment in patients with advanced hepatocellular carcinoma (HCC). This was investigated further in this multicentre study.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, adverse effects, Carcinoma, Hepatocellular, drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Liver Neoplasms, drug therapy, Male, Middle Aged, Octreotide, adverse effects, Quality of Life, Survival Analysis, Treatment Outcome
Référence
Eur. J. Cancer. 2009 Jul;45(10):1788-97